Advertisement
Mayo Clinic Proceedings Home

Hemophilia: A Practical Approach to Genetic Testing

      Hemophilia and von Willebrand disease together account for the large majority of congenital bleeding disorders. Contemporary management, including development of safer clotting factor concentrates and increased emphasis on long-term follow-up in comprehensive hemophilia centers, has improved both quality of life and longevity for patients with congenital bleeding disorders. In addition to facilitating development of recombinant clotting factor concentrates, isolation and characterization of the respective genes have led to increasing availability of a repertoire of genetic tests that, although expensive, are critical for appropriate genetic counseling of affected patients and their family members. This article provides a practical approach to using genetic testing for hemophilia A and B.
      bp (base pair), EGF (epidermal growth factor), kb (kilobase), mRNA (messenger RNA), PCR (polymerase chain reaction), vWD (von Willebrand disease), vWF (von Willebrand factor)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Mann KG
        Biochemistry and physiology of blood coagulation.
        Thromb Haemost. 1999; 82: 165-174
        • Lorentz CP
        • Wieben ED
        • Tefferi A
        • Whiteman DAH
        • Dewald GW
        Primer on medical genomics, part I: history of genetics and sequencing of the human genome.
        Mayo Clin Proc. 2002; 77: 773-782
        • Ensenauer RE
        • Reinke SS
        • Ackerman MJ
        • Tester DJ
        • Whiteman DAH
        • Tefferi A
        Primer on medical genomics, part VIII: essentials of medical genetics for the practicing physician.
        Mayo Clin Proc. 2003; 78: 846-857
        • Soucie JM
        • Evatt B
        • Jackson D
        • Hemophilia Surveillance System Project Investigators
        Occurrence of hemophilia in the United States.
        Am J Hematol. 1998; 59: 288-294
        • Antonarakis SE
        • Kazazian Jr, HH
        The molecular basis of hemophilia A in man.
        Trends Genet. 1988; 4: 233-237
        • White II, GC
        • Rosendaal F
        • Aledort LM
        • Lusher JM
        • Rothschild C
        • Ingerslev J
        • Factor VIII and Factor IX Subcommittee
        Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.
        Thromb Haemost. 2001; 85: 560
        • Mazurier C
        von Willebrand disease masquerading as haemophilia A.
        Thromb Haemost. 1992; 67: 391-396
        • Mazurier C
        • Meyer D
        Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease—results of an international survey.
        Thromb Haemost. 1996; 76: 270-274
        • Ingram GIC
        • Brozovic M
        • Slater NGP
        Bleeding Disorders: Investigation and Management. 2nd ed. Blackwell Scientific Publications, Oxford, England1982: 244-245
        • Furie B
        • Furie BC
        Molecular and cellular biology of blood coagulation.
        N Engl J Med. 1992; 326: 800-806
        • Andrew M
        • Vegh P
        • Johnston M
        • Bowker J
        • Ofosu F
        • Mitchell L
        Maturation of the hemostatic system during childhood.
        Blood. 1992; 80: 1998-2005
        • Levine PH
        Efficacy of self-therapy in hemophilia: a study of 72 patients with hemophilia A and B.
        N Engl J Med. 1974; 291: 1381-1384
        • Mannucci PM
        • Mendolicchio L
        • Gringeri A
        Use of prophylaxis to prevent complications of hemophilia.
        Adv Exp Med Biol. 2001; 489: 59-64
        • Lee C
        Recombinant clotting factors in the treatment of hemophilia.
        Thromb Haemost. 1999; 82: 516-524
        • Aledort LM
        • Levine PH
        • Hilgartner M
        • et al.
        A study of liver biopsies and liver disease among hemophiliacs.
        Blood. 1985; 66: 367-372
        • Soucie JM
        • Symons IV, J
        • Evatt B
        • Brettler D
        • Huszti H
        • Linden J
        • Hemophilia Surveillance System Project Investigators
        Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia.
        Haemophilia. 2001; 7: 198-206
        • Soucie JM
        • Nuss R
        • Evatt B
        • Hemophilia Surveillance System Project Investigators
        • et al.
        Mortality among males with hemophilia: relations with source of medical care.
        Blood. 2000; 96: 437-442
        • Rizza CR
        • Spooner RJ
        • Giangrande PL
        • UK Haemophilia Centre Doctors' Organization (UKCDO)
        Treatment of haemophilia in the United Kingdom 1981-1996.
        Haemophilia. 2001; 7: 349-359
        • Tuddenham EG
        • McVey JH
        The genetic basis of inhibitor development in haemophilia A.
        Haemophilia. 1998; 4: 543-545
        • Thorland EC
        • Drost JB
        • Lusher JM
        • et al.
        Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk.
        Haemophilia. 1999; 5: 101-105
        • Warrier I
        • Ewenstein BM
        • Koerper MA
        • et al.
        Factor IX inhibitors and anaphylaxis in hemophilia B.
        J Pediatr Hematol Oncol. 1997; 19: 23-27
        • Warrier I
        • Lusher JM
        Development of anaphylactic shock in haemophilia B patients with inhibitors.
        Blood Coagul Fibrinolysis. 1998; 9: S125-S128
        • Lenting PJ
        • van Mourik JA
        • Mertens K
        The life cycle of coagulation factor VIII in view of its structure and function.
        Blood. 1998; 92: 3983-3996
        • Goodeve AC
        • Peake IR
        The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development.
        Semin Thromb Hemost. 2003; 29: 23-30
        • Oldenburg J
        • Ananyeva NM
        • Saenko EL
        Molecular basis of haemophilia A.
        Haemophilia. 2004; 10: 133-139
        • Antonarakis SE
        • Rossiter JP
        • Young M
        • et al.
        Factor VIII gene inversions in severe hemophilia A: results of an international consortium study.
        Blood. 1995; 86: 2206-2212
        • Lakich D
        • Kazazian Jr, HH
        • Antonarakis SE
        • Gitschier J
        Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A.
        Nat Genet. 1993; 5: 236-241
        • Bagnall RD
        • Waseem N
        • Green PM
        • Giannelli F
        Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A.
        Blood. 2002; 99: 168-174
        • Gilles JG
        • Jacquemin MG
        • Saint-Remy JM
        Factor VIII inhibitors.
        Thromb Haemost. 1997; 78: 641-646
        • Chowdhury MR
        • Kabra M
        • Menon PS
        Factor IX gene polymorphisms in Indian population.
        Am J Hematol. 2001; 68: 246-248
        • Tefferi A
        • Wieben ED
        • Dewald GW
        • Whiteman DAH
        • Bernard ME
        • Spelsberg TC
        Primer on medical genomics, part II: background principles and methods in molecular genetics.
        Mayo Clin Proc. 2002; 77: 785-808
        • Liu Q
        • Nozari G
        • Sommer SS
        Single-tube polymerase chain reaction for rapid diagnosis of the inversion hotspot of mutation in hemophilia A [letter].
        Blood. 1998; 92: 1458-1459
        • Saiki RK
        • Scharf S
        • Faloona F
        • et al.
        Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia.
        Science. 1985; 230: 1350-1354
        • Buzin CH
        • Wen CY
        • Nguyen VQ
        • et al.
        Scanning by DOVAM-S detects all unique sequence changes in blinded analyses: evidence that the scanning conditions are generic.
        Biotechniques. 2000; 28 (752-753.): 746-750
        • Liu Q
        • Feng J
        • Buzin C
        • et al.
        Detection of virtually all mutations-SSCP (DOVAM-S): a rapid method for mutation scanning with virtually 100% sensitivity.
        Biotechniques. 1999; 26 (936-938, 940-942.): 932
        • Higuchi M
        • Kazazian Jr, HH
        • Kasch L
        • et al.
        Molecular characterization of severe hemophilia A suggests that about half the mutations are not within the coding regions and splice junctions of the factor VIII gene.
        Proc Natl Acad Sci U S A. 1991; 88: 7405-7409
        • Naylor JA
        • Green PM
        • Montandon AJ
        • Rizza CR
        • Giannelli F
        Detection of three novel mutations in two haemophilia A patients by rapid screening of whole essential region of factor VIII gene.
        Lancet. 1991; 337: 635-639
        • Nichols WC
        • Seligsohn U
        • Zivelin A
        • et al.
        Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII.
        Cell. 1998; 93: 61-70
        • Higuchi M
        • Antonarakis SE
        • Kasch L
        • et al.
        Molecular characterization of mild-to-moderate hemophilia A: detection of the mutation in 25 of 29 patients by denaturing gradient gel electrophoresis.
        Proc Natl Acad Sci U S A. 1991; 88: 8307-8311
        • Kraus EM
        • Brettler DB
        Assessment of reproductive risks and intentions by mothers of children with hemophilia.
        Am J Med Genet. 1988; 31: 259-267
        • Ketterling RP
        • Bottema CD
        • Phillips III, JA
        • Sommer SS
        Evidence that descendants of three founders constitute about 25% of hemophilia B in the United States.
        Genomics. 1991; 10: 1093-1096
        • Koeberl DD
        • Bottema CD
        • Sommer SS
        Comparison of direct and indirect methods of carrier detection in an X-linked disease.
        Am J Med Genet. 1990; 35: 600-608
      1. Genetic counseling.
        Am J Hum Genet. 1975; 27: 240-242
        • Biesecker BB
        Goals of genetic counseling.
        Clin Genet. 2001; 60: 323-330
        • Hook CC
        • DiMagno EP
        • Tefferi A
        Primer on medical genomics, part XIII: ethical and regulatory issues.
        Mayo Clin Proc. 2004; 79: 645-650
        • Gilchrist GS
        • Wilke JL
        • Muehlenbein LR
        • Danilenko-Dixon D
        Intrauterine correction of factor VIII (FVIII) deficiency.
        Haemophilia. 2001; 7: 497-499
        • Wertz DC
        • Fanos JH
        • Reilly PR
        Genetic testing for children and adolescents: who decides?.
        JAMA. 1994; 272: 875-881
        • Kulkarni R
        • Lusher JM
        Intracranial and extracranial hemorrhages in newborns with hemophilia: a review of the literature.
        J Pediatr Hematol Oncol. 1999; 21: 289-295
        • Rodriguez V
        • Schmidt KA
        • Slaby JA
        • Pruthi RK
        Intracranial haemorrhage as initial presentation of severe haemophilia B: case report and review of Mayo Clinic Comprehensive Hemophilia Center experience.
        Haemophilia. 2005; 11: 73-77